GlaxoSmithKline plc Sponsored ADR (GSK.US) has filed for a new indication for Bevacizumab injection in China for the treatment of COPD.

Today (February 11), the latest announcement on the official website of China's National Medical Products Administration (CDE) shows that GlaxoSmithKline plc Sponsored ADR (GSK.US) has obtained acceptance for the application for market approval of the anti-IL-5 monoclonal antibody mepolizumab injection under the category 2.2 of biological products. Based on information from GSK's official website and public sources, it is speculated that mepolizumab's indication for the market approval application in China may be Chronic Obstructive Pulmonary Disease (COPD). For this indication, mepolizumab has not yet received approval on a global scale. Source of screenshot: CDE official website Interleukin-5 (IL-5) is a cytokine that regulates the growth, activation, and survival of eosinophils, and provides important signals for the migration of eosinophils from the bone marrow to the lungs and other organs. Public information shows that mepolizumab is the world's first approved anti-IL-5 monoclonal antibody, which binds to IL-5, blocks IL-5 from binding to the surface receptors of eosinophils, inhibits the biological activity of eosinophils and reduces their numbers to normal levels continuously, thereby reducing the growth of eosinophils, as well as eosinophil-mediated inflammation and tissue damage, maintaining health.